Vivek Agnihotri’s ‘The Vaccine War’ Had A Lackluster Day 2, Earning Just Rs 85 Lakh At The Box Office
Summary: On its second day at the box office, Vivek Agnihotri’s latest film, featuring Pallavi Joshi and Nana Patekar, faced ongoing challenges in terms of its collection.
Director Vivek Ranjan Agnnihotri’s most recent project, ‘The Vaccine War’, featuring actors like Pallavi Joshi, Nana Patekar, and Anupam Kher, hit theaters on September 28. Despite the mixed reviews and in contrast to his previous two films, ‘The Kashmir Files’ and ‘The Tashkent Files’, the film had a disappointing start at the box office. According to industry tracker Sacnilk, it managed to accumulate just over Rs 80 lakh on its opening day.
On its second day in theatres, ‘The Vaccine War’ maintained a similar performance, bringing its total two-day earnings to Rs 1.70 crore. The film achieved an overall occupancy rate of 11.77% across India on Friday.
During the extended holiday weekend, which includes Anant Chaturthi (Ganpati Visarjan), Eid Milad Un Nabi, and Gandhi Jayanti on Monday, moviegoers have a multitude of film choices in cinemas. These options include "Chandramukhi 2" starring Kangana Ranaut and Raghava Lawrence, as well as "Fukrey 3" featuring Varun Sharma and Richa Chaddha. This crowded lineup further intensifies the competition for "The Vaccine War."
Even with three new films to choose from, Shah Rukh Khan's "Jawan" and Sunny Deol's "Gadar 2" are still captivating audiences in cinemas across various regions of the country. On its 23rd day in theaters, "Jawan" collected Rs 5.25 crore (net), while "Gadar 2," which has been in theaters for over a month, earned Rs 45 lakh (net) on its 48th day.
"The Vaccine War" is often referred to as the first 'bio-science' film as it attempts to depict the narrative of the scientists behind the creation of India's Covid-19 vaccine, Covaxin, amidst the Covid-19 pandemic. In contrast, Agnihotri's "The Kashmir Files" became a phenomenon through word-of-mouth, accumulating over Rs 340 crore globally in 2022.